Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL.
Talpaz M, et al. Among authors: stone r.
Blood. 2002 Mar 15;99(6):1928-37. doi: 10.1182/blood.v99.6.1928.
Blood. 2002.
PMID: 11877262
Free article.
Clinical Trial.